Reports
Sale
Polycythemia Vera Market Size, Share, Analysis, Forecast: By Type: Dasatinib, Idelalisib, Givinostat, M-009, Others; By Population: Children, Adults; By Treatment: Phlebotomy, Drug Therapy; By Route of Administration: Oral, Parenteral; By End User: Hospitals, Specialty Clinics,Others; Regional Analysis; Supplier Landscape; 2024-2032
Polycythemia Vera Market Outlook
The polycythemia vera market size is expected to grow at a CAGR of 14% during the forecast period of 2024-2032. The market growth is likely to be driven by the advanced research and development activities to develop targeted therapies for patients.
Polycythemia Vera Market Overview
Polycythemia vera is a type of rare blood cancer where the body produces a lot of red blood cells, leading to blood thickening and blood clot formation. Itchiness (especially after a warm bath or shower), numbness, a feeling of fullness or bloating due to enlarged spleen, unusual bleeding are some of the early symptoms. Polycythemia vera belongs to the BCR-ABL1–negative myeloproliferative neoplasms and poses an elevated risk of myelofibrosis progression and acute myeloid leukemia.
Polycythemia Vera Epidemiology
The polycythemia vera prevalence rate is around 22 cases per 100,000 people. It can affect all the ethnic groups, however, the incidence observed is slightly higher among Jewish patients of Eastern European descent than Asians or other Europeans. In United States, it affects around 0.6 to 1.6 per million people. The median age of being affected by the disease is around 60 years of age, with cases being slightly higher in males than females. In younger patients, polycythemia is expected to be higher in people with hemoglobinopathies and congenital cyanotic heart diseases. Consequently, there has been key focus on developing novel therapeutics to meet the high polycythemia vera market demand.
Growth in FDA Approvals for Delivering Quality Treatment
In September 2023, the FDA offered fast track designation to a new polycythemia vera treatment alternative called MWTX-003 (also known as DISC-3405). Developed by Disc Medicine Inc., it is an investigational anti-TMPRSS6 monoclonal antibody developed to increase hepcidin production and suppress serum iron. The rise in number of drugs under clinical trials is expected to boost the polycythemia vera market growth in the forecast period.
Increased Investigation in New Drug Formulas
A University of Birmingham -coordinated trial conducted in May 2023 revealed that Ruxolitinib, a drug that targets JAK2 gene, showed promising results in patients by controlling the blood count and reducing mutated JAK2 by 50%. When compared to existing therapies, Ruxolitinib led to fewer disease related events, slower disease progression and reduced spleen size effectively as well. As there is no permanent cure for the condition and associated, the research activity in new drugs is a key driver for enhanced polycythemia vera market share in upcoming years.
Advancements in Combination Therapies to Manage Treatment Resistance in Patients
Phlebotomy (blood withdrawal through a needle) has been conventionally used in patients. However, the treatment may differ based on a patient’s history of thrombosis and other dynamics. In the case of high-risk disease, cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-α) may be applied to treat inflammation. Furthermore, the polycythemia vera market trend also involves rising technical advances in the biotechnological domain along with a deeper understanding of genetics. Understanding disease modification with respect to cytokine level modulations, along with hematologic, molecular, and histopathologic parameters and their association to clinical outcomes, is a major aspect of research.
Polycythemia Vera Market Segmentation
Market Breakup by Type
- Dasatinib
- Idelalisib
- Givinostat
- M-009
- Others
Market Breakup by Population
- Children
- Adults
Market Breakup by Treatment
- Phlebotomy
- Drug Therapy
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Research Institutes
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Polycythemia Vera Market Regional Analysis
In the forecast period, the United States is expected to dominate the polycythemia vera market. The market size can be attributed to a well-designed medical infrastructure, along with skilled healthcare professionals. The existence of prominent pharmaceutical and biotechnology companies also fosters market growth in the region.
With multiple mergers and acquisitions occurring in the region, Europe is a leading market for polycythemia vera. The presence of proactive authorities, such as the European Medicines Agency, plays a vital role in approving and labeling effective drugs for best possible outcomes in patients. Moreover, the well-structured medical and research infrastructure allows the development of new therapeutic approaches, significantly impacting the market positively. There is immense focus on spreading awareness of the condition via campaigns and programs.
Within the Asia Pacific, Japan is a major market with advanced technologies aiding better understanding the molecular and genetic basis of the disease. However, other emerging economies, such as India, China and South Korea are expected to observe notable polycythemia vera market growth in upcoming years. The growth in market size can be accredited to increasing improvements in the healthcare framework with the help of foreign fundings made in the region. The region is also witnessing a shift towards telemedicine and value-based care, which can play a critical role in fueling market growth.
Polycythemia Vera Market: Competitor Landscape
In August 2023, Agios Pharmaceuticals, Inc., announced their worldwide license agreement with Alnylam Pharmaceuticals, Inc. to commercialise their latest preclinical siRNA targeting TMPRSS6. The potential treatment for polycythemia vera targets TMPRSS6, a key driver of red cell production in the body. The partnership aims to combine Agios’ scientific expertise in rare hematologic diseases with Alnylam’s siRNA platform. The agreement includes an upfront payment of USD 17.5 million to Alnylam and makes it eligible to receive up to USD 130 million in addition sales milestones and other tiered royalties. Similarly, various companies are expanding their research related activities with collaborations and acquisitions to devise improved therapeutics.
The key features of the polycythemia vera market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis
- Jakafi Ltd.
- Imago Biosciences
- ANP Technologies
- Miragen Therapeutics
- AOP Orphan Pharmaceuticals AG
- Incyte Corporation
- PharmaEssentiaI
- Promedior
- Hoffman La Roche Ltd
- Schering-Plough
- Eli Lilly and Company
- Otsuka America Pharmaceutical, Inc
- Zydus Cadila
- Gilead Sciences, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Population |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Polycythemia Vera Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Polycythemia Vera Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Polycythemia Vera Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Polycythemia Vera Epidemiology Forecast (2017-2032)
5.3.1 Germany Polycythemia Vera Epidemiology Forecast (2017-2032)
5.3.2 France Polycythemia Vera Epidemiology Forecast (2017-2032)
5.3.3 Italy Polycythemia Vera Epidemiology Forecast (2017-2032)
5.3.4 Spain Polycythemia Vera Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Polycythemia Vera Epidemiology Forecast (2017-2032)
5.4 Japan Polycythemia Vera Epidemiology Forecast (2017-2032)
6 Polycythemia Vera Market Overview – Seven Major Markets
6.1 Polycythemia Vera Market Historical Value (2017-2023)
6.2 Polycythemia Vera Market Forecast Value (2024-2032)
7 Polycythemia Vera Market Landscape – Seven Major Markets
7.1 Polycythemia Vera Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Polycythemia Vera Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Population
8 Polycythemia Vera Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Polycythemia Vera Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Polycythemia Vera Market Segmentation – Seven Major Markets
11.1 Polycythemia Vera Market by Type
11.1.1 Market Overview
11.1.2 Dasatinib
11.1.3 Idelalisib
11.1.4 Givinostat
11.1.5 M-009
11.1.6 Others
11.2 Polycythemia Vera Market by Population
11.2.1 Market Overview
11.2.2 Children
11.2.3 Adults
11.3 Polycythemia Vera Market by Treatment
11.3.1 Market Overview
11.3.2 Phlebotomy
11.3.3 Drug Therapy
11.4 Polycythemia Vera Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.5 Polycythemia Vera Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Diagnostic Centers
11.5.5 Research Institutes
11.5.6 Others
11.6 Polycythemia Vera Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Polycythemia Vera Market
12.1 Polycythemia Vera Market Historical Value (2017-2023)
12.2 Polycythemia Vera Market Forecast Value (2024-2032)
12.3 Polycythemia Vera Market by Type
12.4 Polycythemia Vera Market by Population
13 EU-4 and United Kingdom Polycythemia Vera Market
13.1 Polycythemia Vera Market Historical Value (2017-2023)
13.2 Polycythemia Vera Market Forecast Value (2024-2032)
13.3 Germany Polycythemia Vera Market Overview
13.3.1 Polycythemia Vera Market by Type
13.3.2 Polycythemia Vera Market by Population
13.4 France Polycythemia Vera Market Overview
13.4.1 Polycythemia Vera Market by Type
13.4.2 Polycythemia Vera Market by Population
13.5 Italy Polycythemia Vera Market Overview
13.5.1 Polycythemia Vera Market by Type
13.5.2 Polycythemia Vera Market by Population
13.6 Spain Polycythemia Vera Market Overview
13.6.1 Polycythemia Vera Market by Type
13.6.2 Polycythemia Vera Market by Population
13.7 United Kingdom Polycythemia Vera Market Overview
13.7.1 Polycythemia Vera Market by Type
13.7.2 Polycythemia Vera Market by Population
14 Japan Polycythemia Vera Market
14.1 Polycythemia Vera Market Historical Value (2017-2023)
14.2 Polycythemia Vera Market Forecast Value (2024-2032)
14.2.1 Polycythemia Vera Market by Type
14.2.2 Polycythemia Vera Market by Population
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Novartis
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Jakafi Ltd.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Imago Biosciences
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 ANP Technologies
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Miragen Therapeutics
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 AOP Orphan Pharmaceuticals AG
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Incyte Corporation
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 PharmaEssentiaI
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Promedior
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Hoffman La Roche Ltd
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Schering-Plough
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Eli Lilly and Company
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Otsuka America Pharmaceutical, Inc
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Zydus Cadila
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Gilead Sciences, Inc.
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Polycythemia Vera Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 14% during the forecast period of 2024-2032, driven by the advanced research and development activities to develop targeted therapies for patients.
The market demand is driven by growing incidence of the condition, owing to increased genetic mutations in the population, along with rising competition between pharmaceutical companies to commercialise and develop innovative and effective solutions. Increased awareness initiatives via government, non-profit organisations and influential healthcare companies play a critical role to boost market demand as well.
The major market trend involves increasing frequency of drugs in clinical trials, developed to offer personalised treatment options to patients. One such drug is Ruxolitinib, created by the researchers at the University of Birmingham and led to slower progression of the disease.
Based on types, the market is divided into Dasatinib, Idelalisib, Givinostat, and M-009, among others.
Major end users include hospitals and clinics, among others.
It includes children as well as adults.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Novartis, Jakafi Ltd., Imago Biosciences, ANP Technologies, Miragen Therapeutics, AOP Orphan Pharmaceuticals AG, Incyte Corporation, PharmaEssentiaI, Promedior, Hoffman La Roche Ltd., Schering-Plough, Eli Lilly and Company, Otsuka America Pharmaceutical, Inc., Zydus Cadila and Gilead Sciences, Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER